The acquisition will strengthen the long-term durability of the company’s domestic supply chain, helping to ensure Americans can consistently access personalized medications SAN FRANCISCO--(BUSINESS ...

Hims & Hers announced it has acquired a U.S.-based peptide facility based in California. The company said the acquisition will enable the ...

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

Raising its price target on the shares to $21, reports The Fly, BofA nonetheless reiterated an "underperform" ( i.e., sell) ...

We believe there is minimal cause for concern with HIMS stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...

Hims & Hers, a health and wellness platform, is set to introduce at-home lab testing capabilities through the acquisition of ...

Telehealth pioneer Hims & Hers Health (HIMS) stock is soaring, with a 12% gain in recent days and a whopping 176% in the last ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...

Amplify Online Retail ETF reflects digital trends but faces stagnant growth. Learn why IBUY's exposure to economic challenges ...

With the formation of the BJP government in Delhi, an action plan has been prepared to introduce key reforms in the healthcare sector, which includes digitisation of health services, setting up of ...

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report)’s share price hit a new 52-week high during trading on Wednesday after Bank of America raised their price target on the stock from $18.00 to $21.